DE60014869T2 - Methode und zusammenstellung zur prophylaxe der narbenbildung bei glaukomatösen filtrationsblasen und drainagefisteln - Google Patents
Methode und zusammenstellung zur prophylaxe der narbenbildung bei glaukomatösen filtrationsblasen und drainagefisteln Download PDFInfo
- Publication number
- DE60014869T2 DE60014869T2 DE60014869T DE60014869T DE60014869T2 DE 60014869 T2 DE60014869 T2 DE 60014869T2 DE 60014869 T DE60014869 T DE 60014869T DE 60014869 T DE60014869 T DE 60014869T DE 60014869 T2 DE60014869 T2 DE 60014869T2
- Authority
- DE
- Germany
- Prior art keywords
- prostaglandin
- pga
- pgj
- use according
- prostaglandins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001914 filtration Methods 0.000 title claims description 18
- 238000000034 method Methods 0.000 title abstract description 9
- 238000011321 prophylaxis Methods 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 51
- 238000001356 surgical procedure Methods 0.000 claims abstract description 26
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 22
- 206010016717 Fistula Diseases 0.000 claims abstract description 7
- 230000003890 fistula Effects 0.000 claims abstract description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 33
- 230000037390 scarring Effects 0.000 claims description 14
- -1 isopropyl ester Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 6
- VHRUMKCAEVRUBK-WKELIDJCSA-N (z)-7-[(1s,5e)-5-[(z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC\C=C/C=C1\[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-WKELIDJCSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 1
- 208000002352 blister Diseases 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 description 22
- 238000011282 treatment Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 2
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 2
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TUXFWOHFPFBNEJ-GJGHEGAFSA-N 13,14-dihydro-Delta(12)-prostaglandin J2 Chemical compound CCCCC[C@H](O)C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O TUXFWOHFPFBNEJ-GJGHEGAFSA-N 0.000 description 1
- CTQQHQGBBMYJPT-DZFVFWAGSA-N 16,16-dimethyl-PGA1 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O CTQQHQGBBMYJPT-DZFVFWAGSA-N 0.000 description 1
- MOTPSJUHMGPRFZ-QEJIITRLSA-N 16,16-dimethyl-PGA2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MOTPSJUHMGPRFZ-QEJIITRLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical compound [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- MYNMJEGQTXQGKQ-RXMNKVFOSA-N propan-2-yl (z)-7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopent-3-en-1-yl]hept-5-enoate Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(=O)OC(C)C MYNMJEGQTXQGKQ-RXMNKVFOSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9900672A SE9900672D0 (sv) | 1999-02-25 | 1999-02-25 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| SE9900672 | 1999-02-25 | ||
| PCT/SE2000/000357 WO2000050040A1 (en) | 1999-02-25 | 2000-02-23 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60014869D1 DE60014869D1 (de) | 2004-11-18 |
| DE60014869T2 true DE60014869T2 (de) | 2006-03-09 |
Family
ID=20414625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60014869T Expired - Fee Related DE60014869T2 (de) | 1999-02-25 | 2000-02-23 | Methode und zusammenstellung zur prophylaxe der narbenbildung bei glaukomatösen filtrationsblasen und drainagefisteln |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6495563B1 (https=) |
| EP (1) | EP1161245B1 (https=) |
| JP (1) | JP2003521467A (https=) |
| AT (1) | ATE279197T1 (https=) |
| AU (1) | AU767411B2 (https=) |
| CA (1) | CA2363131A1 (https=) |
| DE (1) | DE60014869T2 (https=) |
| SE (1) | SE9900672D0 (https=) |
| WO (1) | WO2000050040A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162417A1 (en) * | 2007-12-21 | 2009-06-25 | Cook Incorporated | Drug eluting ocular conformer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981880A (en) * | 1969-03-14 | 1976-09-21 | The Upjohn Company | Racemic prostaglandins of the 2-series and analogs thereof |
| US3954844A (en) | 1975-01-03 | 1976-05-04 | G. D. Searle & Co. | (5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9.13-trien-1-oic acid and esters |
| JPS58216155A (ja) * | 1982-06-10 | 1983-12-15 | Ono Pharmaceut Co Ltd | 新規なプロスタグランジンｄ類似化合物 |
| DE3785602T2 (de) | 1986-03-13 | 1993-09-02 | Univ Columbia | Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom. |
| DE3850676T2 (de) | 1987-09-18 | 1994-11-03 | Ueno Seiyaku Oyo Kenkyujo Kk | Hypotensive okulare Mittel. |
| DE1300150T1 (de) * | 1988-09-06 | 2003-09-18 | Pharmacia Ab, Stockholm | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
| DE68928551T2 (de) | 1988-10-01 | 1998-04-23 | Ueno Seiyaku Oyo Kenkyujo Kk | Oculare hypotensive Mittel |
| CA2071137A1 (en) * | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| SE9401087D0 (sv) * | 1994-03-31 | 1994-03-31 | Pharmacia Ab | New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| SE9403158D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | New use of prostaglandins |
-
1999
- 1999-02-25 SE SE9900672A patent/SE9900672D0/xx unknown
-
2000
- 2000-02-23 EP EP00911536A patent/EP1161245B1/en not_active Expired - Lifetime
- 2000-02-23 CA CA002363131A patent/CA2363131A1/en not_active Abandoned
- 2000-02-23 US US09/913,849 patent/US6495563B1/en not_active Expired - Fee Related
- 2000-02-23 DE DE60014869T patent/DE60014869T2/de not_active Expired - Fee Related
- 2000-02-23 JP JP2000600651A patent/JP2003521467A/ja not_active Withdrawn
- 2000-02-23 WO PCT/SE2000/000357 patent/WO2000050040A1/en not_active Ceased
- 2000-02-23 AT AT00911536T patent/ATE279197T1/de not_active IP Right Cessation
- 2000-02-23 AU AU33402/00A patent/AU767411B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE9900672D0 (sv) | 1999-02-25 |
| WO2000050040A1 (en) | 2000-08-31 |
| EP1161245B1 (en) | 2004-10-13 |
| EP1161245A1 (en) | 2001-12-12 |
| ATE279197T1 (de) | 2004-10-15 |
| WO2000050040A8 (en) | 2003-02-06 |
| DE60014869D1 (de) | 2004-11-18 |
| AU3340200A (en) | 2000-09-14 |
| CA2363131A1 (en) | 2000-08-31 |
| US6495563B1 (en) | 2002-12-17 |
| JP2003521467A (ja) | 2003-07-15 |
| AU767411B2 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69530594T2 (de) | Verfahren und mittel zur arzneistoffverabreichung | |
| DE68929435T2 (de) | Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension | |
| EP1455803B2 (de) | Verwendung von panthenol und/oder panthothensäure und hyaluronsäure/und oder hyaluronat zur herstellung einer pharmazeutischen zusammensetzung zur ophtalmologischen anwendung | |
| DE69634414T2 (de) | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie | |
| DE68902649T2 (de) | Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen. | |
| DE69317537T2 (de) | Antiallergische Zusammensetzung zur ophthalmischen oder nasalen Anwendung | |
| DE69828993T2 (de) | Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer | |
| DE69326610T2 (de) | Arzneimittel gegen glaukom | |
| DE69807281T2 (de) | Difluprednat enthaltende Zusammensetzungen | |
| DE3785602T2 (de) | Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom. | |
| EP0365571A1 (de) | Arzneimittel zur behandlung des auges und dazu geeignetes trägermaterial | |
| EP1453523B1 (de) | Heparin-haltiges ophthalmikum | |
| CH652598A5 (de) | Antiinflammatorische ophthalmische loesung. | |
| DE69535081T2 (de) | Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis | |
| WO1997038674A1 (de) | Ophthalmische zusammensetzung mit verlängerter verweilzeit am auge | |
| DE60002719T2 (de) | Ophthalmische zusammensetzungen in form wässriger gele | |
| DE69323202T2 (de) | Ophthalmologische zubereitungen | |
| DE3440352A1 (de) | Dry-eye-packung | |
| EP0585896B1 (de) | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks | |
| DE60205913T2 (de) | Ophthalmische zubereitung mit n-acetylcystein zur behandlung trockener augen | |
| DE69834638T2 (de) | Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom | |
| DE60132325T2 (de) | Ophthalmische lösung | |
| WO2003099258A1 (de) | Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol | |
| EP0068160B1 (de) | Verwendung von 1-(p-Isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur Herstellung eines Arzneimittels zur Senkung des Augeninnendrucks | |
| DE60005992T2 (de) | Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |